Equity Research, Broker Reports, and media content on ABBVIE INC

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about ABBVIE INC
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on ABBVIE INC. We currently have 0 research reports from 0 professional analysts.

Date Source Announcement
06Dec16 03:30 PRN Late-Breaking Ibrutinib (IMBRUVICA®) Data Show Complete or Partial Response in Two-Thirds of Patients with Chronic Graft-Versus-Host-Disease, a Frequent and Potentially Life-Threatening Complication of Stem Cell Transplant
06Dec16 02:15 PRN New Phase 2 Data Show Nearly Half of Patients with Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond to Treatment with Ibrutinib (IMBRUVICA®)
05Dec16 01:55 PRN AbbVie and Johns Hopkins to Collaborate on Cancer Research
05Dec16 01:50 PRN AbbVie and Northwestern University's Lurie Cancer Center to collaborate on multi-year cancer research agreement
05Dec16 12:30 PRN Favorable Response Rates Suggest Promise of Ibrutinib (IMBRUVICA®) Combination Therapy in Two Common Types of Non-Hodgkin's Lymphoma
30Nov16 07:00 PRN AbbVie Receives Orphan Drug Designation for Investigational IL-23 Inhibitor Risankizumab from the U.S. Food and Drug Administration for the Treatment of Pediatric Patients with Crohn's Disease
15Nov16 01:00 PRN AbbVie's Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease
  • Frequency of research reports


  • Research reports on


  • Providers covering